Incyte acquires Villaris Therapeutics for $1.43 billion
ADC评论
October 4, 2022
On October 3, Incyte announced the acquisition of Villaris Therapeutics, which was invested and incubated by Medicxi, and acquired the latter’s anti-IL-15Rβ monoclonal antibody drug
